{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Is a congenital abnormality or birth defect.', 'Other: Medically significant events, which do not meet any of the criteria above, but', 'may jeopardize the patient and may require medical or surgical intervention to prevent', 'one of the other serious outcomes listed in the definition above. Examples of such events', 'are blood dyscrasias (e.g., neutropenia or anemia requiring blood transfusion, etc.) or', 'convulsions that do not result in inpatient hospitalization.', 'Suspected Unexpected Serious Adverse Reactions (SUSARs) and Unexpected Adverse', 'Reactions: Any suspected adverse reaction that is serious, unexpected, and considered to be', 'related to drug exposure is defined as a SUSAR.', 'An unexpected AE is any adverse drug event, which is not listed in the current IB or is not', 'listed at the specificity or intensity that has been observed.', 'Suspected adverse reaction means any AE for which there is a reasonable possibility that the', 'drug caused the AE.', 'An untoward and unintended post-dosing response to a non-trial drug is, by definition, not a', 'SUSAR, but is, however, an AE.', 'Each AE is to be evaluated for duration, severity, seriousness and causal relationship to the', 'IMP or trial procedures. The action taken with the investigational drug and the outcome of', 'the event must also be recorded.', 'Treatment-emergent adverse event (TEAE): Any AE temporally associated with the use of', 'IMP, whether considered related to the IMP or not. TEAEs are recorded from the start of', \"IMP administration, until completion of the patient's last visit.\", 'Overdose', 'For the purposes of this trial, exceeding the dosage requirements specified in this protocol', 'represents an overdose (see Section 6.1). In case of suspected overdose, the patient should be', \"treated according to standard medical practice based on the Investigator's judgment.\", 'Severity', 'All AEs observed will be graded using the National Cancer Institute (NCI) Common', 'Terminology Criteria for Adverse Events (CTCAE) version 5.0. The NCI CTCAE is a', 'descriptive terminology, which can be utilized for AE reporting. A grading (severity) scale is', \"provided for each AE term. Grade refers to the severity of the AE. If a particular AE's\", 'severity is not specifically graded by the guidance document, the Investigator is to use the', 'general NCI-CTCAE definitions of Grade 1 through Grade 5 following his or her best', 'medical judgment. The CTCAE displays Grades 1 through 5 with unique clinical', 'descriptions of severity for each AE based on the following general guideline:', 'Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations', 'only; intervention not indicated.', 'argenx BVBA', 'Confidential', 'Page 79 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-', 'appropriate instrumental activities of daily living (ADL).', 'Grade 3: Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care', 'ADL.', 'Grade 4: Life-threatening consequences; urgent intervention indicated.', 'Grade 5: Death related to AE.', 'Relationship', 'The causal relationship between the IMP/trial procedures and the AE has to be characterized', 'as unrelated, unlikely, related, possible, and probable.', 'Events can be classified as \"unrelated\" if there is not a reasonable possibility that the', 'IMP caused the AE.', 'An \"unlikely\" relationship suggests that only a remote connection exists between the', 'IMP and the reported AE. Other conditions, including chronic illness, progression or', 'expression of the disease state, or reaction to concomitant medication, appear to explain', 'the reported AE.', 'A \"related\" relationship suggests that the AE follows a reasonable temporal sequence', 'from administration of IMP, it follows a known or expected response pattern to the IMP,', \"and it cannot reasonably be explained by known characteristics of patient's clinical state.\", 'A \"possible\" relationship suggests that the association of the AE with the IMP is', 'unknown; however, the AE is not reasonably supported by other conditions.', 'A \"probable\" relationship suggests that a reasonable temporal sequence of the AE with', \"drug administration exists and, in the Investigator's clinical judgment, it is likely that\", 'a', 'causal relationship exists between the drug administration and the AE, and other', 'conditions (concurrent illness, progression or expression of disease state, or concomitant', 'medication reactions) do not appear to explain the AE.', 'In final evaluation for reporting, the relationship will be converted into \"Binary', 'Determination\" as per Council of International Organizations of Medical Sciences (CIOMS).', 'Unrelated and Unlikely will be clubbed into \"Unrelated\" and Related, Possible and Probable', 'will be clubbed into \"Related\" for final reporting purpose.', '7.2.1.1. Adverse Events of Special Interest', 'An AESI (serious or non-serious, related or not related) is an event of scientific and medical', \"concern specific to the sponsor's product or program.\", 'argenx BVBA', 'Confidential', 'Page 80 of 110']\n\n###\n\n", "completion": "END"}